On June 8, 2021 AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, reported data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM) (Press release, AIVITA Biomedical, JUN 8, 2021, View Source [SID1234583699]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The analysis focused on the 57 Phase 2 patients who received eight doses of AV-GBM-1 over approximately six months. At the time of the analysis, surviving patients had completed therapy and had been followed between 10.1 and 27.6 months from enrollment. The median length of PFS was 10.4 months (95% confidence interval; 8.6 to 11.7 months), an improvement of approximately 50% compared to a median PFS of 6.9 months (95% confidence interval; 5.8 to 8.2 months) in the landmark STUPP study1 that established the standard of care for patients with newly diagnosed GBM. This represents a 42% reduction in the risk of progression or death at 6.9 months. Median survival has not been reached and will be assessed after the final patient has a minimum follow up of 15 months. Overall, the treatment was well tolerated. There were 54 serious adverse events among 28 of 57 patients but none were attributed to the vaccine.
"The potential for AV-GBM-1 to significantly improve PFS in newly diagnosed GBM patients over and above current standard of care is very encouraging," said Robert O. Dillman, M.D., chief medical officer of AIVITA. "We look forward to confirming this benefit in a randomized Phase 3 multi-center trial."
AV-GBM-1 is a novel immunotherapy consisting of autologous dendritic cells loaded with autologous tumor neoantigens derived from self-renewing tumor-initiating cells isolated from tumors after routine surgical debulking. The treatment is administered to patients via subcutaneous injection. The treatment is uniquely pan-antigenic, targeting multiple antigens, including all neoantigens, from autologous tumor-initiating cells that are responsible for the tumor growth.
"This milestone is an encouraging first step in the fight against GBM, a disease that has a devastating impact on patients and their families," said study principal investigator Daniela Bota, M.D., Ph.D., director, University of California, Irvine (UCI) Alpha Stem Cell Clinical and medical director, UCI Health Comprehensive Brain Tumor Program.
AIVITA is currently conducting two clinical studies in the United States investigating its platform immunotherapy in patients with GBM and melanoma.
1. Stupp R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.